Cancer drug sales lift Genentech quarterly profit (Reuters)
11th Jan 2006, 14:52 GMT
Reuters - Genentech Inc. on Tuesday reported fourth-quarter profit rose 64 percent on strong sales of its cancer medicines, but colon cancer drug Avastin fell short of Wall Street expectations and the company's shares fell more than 2 percent after hours.
Cancer drug sales lift Genentech quarterly profit (Reuters) related news:
- Cancer drug sales lift Genentech quarterly profit — washingtonpost.com -
- Cancer Drugs Lift Earnings at Genentech — NYT > Business
- Genentech sales and profit soar — Latest news from San Francisco Business Times
- Genentech: Avastin sales hard to predict — MarketWatch.com - Top Stories
- Intel expected to show higher quarterly profit (Reuters) — Yahoo! News: Semiconductor Industry & Servers
- Intel expected to show higher quarterly profit — Reuters: Business
- Genentech Falls 4% on Avastin — Red Herring
- Former worker sues Genentech over drug marketing — News -- SiliconValley.com
- Ex-Worker Sues Genentech Over Marketing — washingtonpost.com -
- Genentech Reports High Profit, But Still Disappoints — FOXNews.com - Business
Latest news from Yahoo! News: Earnings News:
- Tyson Foods posts 4th-quarter loss (AP)
- Disney Doubles Quarterly Profit (BusinessWeek Online)
- Tyson Foods posts third straight quarterly loss (Reuters)
- Tyson Foods posts another loss, but sees 07 profits (Reuters)
- Tyson posts 4Q loss (AP)
- Ford to discuss earnings restatement (AP)
- Earnings drive European equities higher (FT.com)
- Tyson Foods posts third consecutive loss (AP)
- Tyson Foods sees higher meat prices (AP)
- Vodafone pleases as H1 earnings top forecasts (Reuters)